Denmark · Delayed Price · Currency is DKK ALK-Abelló Earnings Call Transcripts
Fiscal Year 2026
-
Strong revenue and profit growth in 2025 enabled a resumed dividend and continued investment in R&D, production, and sustainability. All board proposals, including an updated remuneration policy and board re-elections, were approved. Shareholders discussed production, AI, and market expansion.
Fiscal Year 2025
-
Strong 2025 results with 15% revenue growth, 26% EBIT margin, and robust expansion in tablets and anaphylaxis products. 2026 guidance targets 11–15% revenue growth, continued double-digit tablet and anaphylaxis sales, and ongoing investment in R&D and infrastructure.
-
Q3 delivered double-digit revenue and EBIT growth, driven by strong pediatric tablet launches, new partnerships, and robust performance across all regions and product lines. The full-year outlook was raised, with continued investment in growth initiatives and a strong balance sheet.
-
Q2 delivered strong revenue and EBIT growth, driven by pediatric tablet launches and adrenaline auto-injectors, prompting an upgraded full-year outlook. Europe and North America led segment growth, with new product rollouts and strategic partnerships supporting momentum.
-
A specialty pharma group targets over 10% annual growth through 2028, driven by pediatric and adult allergy tablets, new launches like Nefy, and expansion into food allergy. Strategic partnerships and business development are central, with a strong focus on Europe and innovation.
-
Q1 saw 12% revenue growth and a 50% EBIT increase, driven by strong tablet sales and successful pediatric launches. Guidance for 2025 remains confident, with double-digit tablet growth and margin improvements expected, despite macroeconomic uncertainties.
-
Strong financial growth in 2024 was driven by tablet sales and strategic execution, with a focus on reinvestment over dividends. The board and auditor were re-elected, and the Allergy Plus strategy aims for continued expansion and sustainability.
Fiscal Year 2024
-
Revenue grew 15% year-over-year, driven by strong European tablet sales and strategic execution, with EBIT up 65% and margin expansion. 2025 guidance projects 9%-13% revenue growth and a 25% EBIT margin, with Neffy and pediatric launches as key drivers.
-
Q3 delivered 18% organic revenue growth and a 10-point EBIT margin increase, driven by strong tablet sales and Jext recovery. Full-year guidance is maintained, with major strategic moves including the Neffy in-licensing and advances in food allergy trials.
-
Secured exclusive rights to Neffy, a needle-free adrenaline nasal spray, targeting major growth in the anaphylaxis market, with launches in Europe and Canada from 2025. The deal is expected to be earnings-accretive within a few years and supports long-term strategic and financial goals.
-
Q2 saw 21% organic revenue growth, led by strong tablet sales in Europe, driving upgrades to full-year revenue and EBIT margin guidance. The Allergy+ strategy is progressing, with regulatory advances for pediatric tablets and ongoing cost optimization supporting long-term growth.
-
The updated strategy targets doubling patient reach by 2030, sustained double-digit sales growth, and a 25% EBIT margin. Expansion in pediatric, food allergy, and anaphylaxis, plus digital and R&D investments, underpin growth, while disciplined capital allocation and operational optimization support long-term value creation.